Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 6 of 12, showing 10 Applications out of 119 total, starting on record 51, ending on 60

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

51.

ECCT/24/07/02   TMC278LAHTX4002
    A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Longacting Combination Therapy Studies   
Principal Investigator(s)
1. Reena Shah
Site(s) in Kenya
1. Aga Khan University Hospital Nairobi (Nairobi City county)
2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county)
3. Kenya Medical Research Institute-Walter Reed Program (KEMRI-WRP) Clinical Research Site, Kericho, Kenya (Kericho county)
4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county)
5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Nairobi City county)
 
16-04-2025 View

52.

ECCT/25/07/05   Cabotegravir + Rilpivirine Lon
    A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Longacting Combination Therapy Studie   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Aga Khan University Hospital (Nairobi City county)
2. Moi University Clinical Research Centre (Elgeyo/Marakwet county)
3. KEMRI-WRP (Kericho county)
4. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
 
31-10-2025 View

53.

ECCT/24/10/05   Cabotegravir + Rilpivirine Inj
    A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long-acting Combination Therapy Studies   
Principal Investigator(s)
1. Abraham Siika
Site(s) in Kenya
1. Aga Khan University Hospital Nairobi (Nairobi City county)
2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county)
3. Kenya Medical Research Institute-Walter Reed Program (KEMRI-WRP) Clinical Research Site, Kericho (Kericho county)
4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county)
5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
 
29-04-2025 View

54.

ECCT/24/10/04   Cabotegravir + Rilpivirine Inj
    A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long-acting Combination Therapy Studies   
Principal Investigator(s)
1. Josphat Kosgei
Site(s) in Kenya
1. Kenya Medical Research Institute/Walter Reed Project Clinical Research Centre (Kericho county)
2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county)
3. Aga Khan University Hospital Nairobi (Nairobi City county)
4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county)
5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
 
30-04-2025 View

55.

ECCT/21/07/01   RESOLVE
    A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell DiseaseA Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Jessie Nyokabi Githanga
Site(s) in Kenya
1. Strathmore University Medical Center (Nairobi City county)
2. KEMRI Kondele children\'S Hospital (Kisumu county)
3. Gertrude\'s Children\'s Hospital (Nairobi City county)
 
10-11-2021 View

56.

ECCT/21/10/02   RESOLVE
    A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Janet Oyieko
Site(s) in Kenya
1. KEMRI CCR- Butere County Hospital (Kisumu county)
2. Strathmore University (Nairobi City county)
3. KEMRI Kondele Children’s Hospital (Kisumu county)
4. KEMRI/CRDR Siaya Clinical Research Annex (Siaya county)
5. KEMRI CRDR Clinical Research Clinic Nairobi (Nairobi City county)
6. Gertrude’s Children’s Hospital (Nairobi City county)
 
14-07-2022 View

57.

ECCT/21/11/06   RESOLVE
    A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell Disease    
Principal Investigator(s)
1. Videlis Nduba
Site(s) in Kenya
1. KEMRI/CRDR Siaya Clinical Research Annex (Siaya county)
2. KEMRI CRDR Clinical Research Clinic Nairobi (Nairobi City county)
 
20-05-2022 View

58.

ECCT/24/01/03   Doxy Short Course
    A Phase 4 Study of a 3-Day Vs. 7-Day Regimen of Doxycycline for the Treatment of Chlamydial Infection.   
Principal Investigator(s)
1. Jackson Nyangaresi Nyandoro
2. Nelly Rwamba Mugo
Site(s) in Kenya
1. Pwani Research Centre (Mombasa county)
2. KEMRI CCR-PHRD (Nairobi City county)
 
18-06-2024 View

59.

ECCT/21/03/03   PrEP My Way
    A Novel PrEP Delivery System to Meet the Needs of Young African Women   
Principal Investigator(s)
1. Prof. Elizabet Ann Bukusi
Site(s) in Kenya
Kisumu
 
06-07-2021 View

60.

ECCT/15/10/02  
    A non-randomized, open label, single dose, pharmacokinetics, safety and tolerability study of Captopril 50mgs in healthy Kenyan Adults.   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
Site(s) in Kenya
KEMRI centre for clinical Research
 
02-12-2015 View